GLP-1 / Semaglutide (Gastric & Neuroendocrine Modulators)

Phase 3 Cardiovascular Outcome Trials: Analysis of once‑weekly and oral semaglutide for major adverse cardiac events in type 2 diabetes across SUSTAIN and PIONEER programs.
— https://pubmed.ncbi.nlm.nih.gov/30615985/

Preclinical Receptor Binding Kinetics: Pharmacological reviews detailing GLP‑1 receptor internalization, biased signaling, and tissue‑specific activation.
— https://pubmed.ncbi.nlm.nih.gov/39347905/

Integrated Safety Meta‑Analyses: Pooled real‑world data from Nature Medicine, BMC Cardiovascular Disorders, and FDA adverse event databases (2023‑2025).
— https://bmccardiovasclidord.biomedcentral.com/articles/10.1186/s12872-025-05278-3

FDA Regulatory Prescribing Labels: Official dosing, titration, and safety information for Ozempic®, Wegovy®, and Rybelsus® (2017‑2025 updates).
— https://www.ncbi.nlm.nih.gov/books/NBK603723/

Clinical & Real‑World Meta‑Analyses (2024‑2025): Comprehensive reviews from J Endocrinol Invest, Obes Rev, Eur J Prev Cardiol, and multiple cardiometabolic journals.
— https://pubmed.ncbi.nlm.nih.gov/39347905/

Preclinical Organ‑Protective Studies: JCI Insight 2021, Neuropsychopharmacology 2025, and J Diabetes Complications 2023 examining pancreatic, neural, and renal outcomes.
— https://insight.jci.org/articles/view/133429

FDA Compounding Safety Alerts & StatPearls Summary: Official communications on dosing errors and clinical practice guidelines for compounded semaglutide.
— https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded

GLP‑2 / Tirzepatide (Dual‑Agonist Metabolic Modulators)

Late‑Stage Obesity & Diabetes Trials: SURMOUNT‑1‑5 (NEJM 2022‑2025) and SURPASS‑1‑5 (Lancet/JAMA 2021‑2022) evaluating dual GIP/GLP‑1 agonism for weight and glycemic control.
— https://hyresearch.com/product/bpc-157/

Mechanistic & Receptor Pharmacology Reviews: JCI Insight 2020 and Cardiovasc Diabetol 2022 detailing co‑agonist signaling bias and adipose tissue cross‑talk.
— https://cardiab.biomedcentral.com/articles/10.1186/s12933-022-01604-7 ; https://pubmed.ncbi.nlm.nih.gov/33325008/

Meta‑Analyses & Long‑Term Safety: Frontiers Endocrinol 2025, Int J Obes 2023‑2025, and JAMA Netw Open 2024 on cardiovascular, gastrointestinal, and hepatic outcomes.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/

FDA Prescribing Information (Mounjaro® / Zepbound®): Label updates (2022‑2025) for type 2 diabetes and chronic weight management with tirzepatide.
— https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf

Preclinical Multi‑Organ Effects: Cardiovasc Diabetol 2022, Adv Sci 2025, JCI Insight 2021, Nature Metab 2023, and Cell Metab 2024 exploring pancreatic, hepatic, and neural targets.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC10122586/

Synthesis & Pharmacokinetic Profiling: Org Process Res Dev 2021, Eur J Pharm Sci 2024, J Clin Pharmacol 2024, and FDA Clinical Pharmacology Review on tirzepatide absorption and clearance.
— https://pubs.acs.org/doi/10.1021/acs.oprd.1c00108

Appetite Suppression & Glucose Regulation: Diabetes Care 2023, Lancet 2021, and StatPearls 2024 reporting caloric intake reduction and HbA1c improvements.
— https://diabetesjournals.org/care/article/46/5/998/148546/Tirzepatide-Reduces-Appetite-Energy-Intake-and-Fat

Purity & Storage Validation: Manufacturer data from Manufactory 2025, Pura Peptides, Encompass Peptides, and BioEdge Research Labs confirming high‑purity research material.
— https://www.manufactry.com/tirzepatide/high-purity-tirzepatide-10mg-glp-1-agonist-peptide-for-research-use_2149743.html

BPC‑157 (Gastrointestinal & Tendon Repair Pentadecapeptide)

Preclinical Systematic Reviews: PubMed meta‑analyses covering gastric protection, tendon‑to‑bone healing, and colitis models (Curr Pharm Des 2019; J Orthop Surg Res 2025; Regul Pept 2010).
— https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/

Early Pilot Human Observational Studies: Case series and open‑label reports in Altern Ther Health Med (2021,2024,2025) and Med Hypotheses 2021 assessing safety and efficacy.
— https://pubmed.ncbi.nlm.nih.gov/29998800/

FDA Regulatory Status & Safety Reviews: Bulk drug substance listings (2023‑2025) and PMC toxicology reports (Pharmaceuticals 2025; Regul Toxicol Pharmacol 2020).
— https://www.researchchemical.com/product/bpc-157-peptide/

Inflammatory Bowel & Joint Injury Models: PMC 2017, Curr Pharm Des 2020, J Physiol Paris 2021, Inflammopharmacology 2006, and Regul Toxicol Pharmacol 2020 examining gut and tendon repair.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC5333585/

Synthesis & Laboratory Handling Protocols: Drug Des Devel Ther 2015, ProSpec Bio 2025, Phoenix Pharm 2025, and Pure Health Peptides 2024 outlining peptide stability and storage.
— https://www.mdpi.com/1424-8247/18/2/185

Melanotan (Melanocortin‑1 Receptor Agonist)

Melanoma Case Series & Toxicological Reports: Hjuler & Lorentzen (2014) melanoma case; Alsabbagh et al. (2025) mucosal melanoma; Nelson et al. (2012) acute toxicity.
— https://pubmed.ncbi.nlm.nih.gov/24355990/

Phase I & II Clinical Trials (Erectile Function / Tanning): Wessells et al. (2000,2005) on libido and sexual function; Dorr et al. (1996) UV‑induced tanning; Hadley & Dorr (2006) therapeutic review.
— https://pubmed.ncbi.nlm.nih.gov/11035391/

Integrated Safety & Renal Infarction Cases: Dorr et al. (1996) Phase I tanning; Wessells et al. (2000) ED study; Peters et al. (2020) renal infarction; Hjuler & Lorentzen (2014) melanoma.
— https://pubmed.ncbi.nlm.nih.gov/8637402/

TB‑500 (Thymosin Beta‑4 Derivative – Actin Regulation)

Multi‑Functional Mechanistic Review (Goldstein 2012): Covers actin sequestration, wound healing, angiogenesis, and hair follicle cycling in preclinical models.
— https://pubmed.ncbi.nlm.nih.gov/22074294/

Analytical Chemistry & Doping Detection: Thevis et al. (2012) synthesis and mass spec; Wang et al. (2021) Phase I safety; Ho et al. (2012) equine urinary detection.
— https://pubmed.ncbi.nlm.nih.gov/22962027/

Recent Anti‑Aging & Cardiac Remodeling Studies: Ueki (2021) anti‑aging peptides; Maar et al. (2025) cardiac fibrosis; Ti et al. (2015) diabetic angiogenesis; WADA metabolism report.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC8228050/

Safety & Metabolism Summaries: Peptides.org (2025), Innerbody (2025) TB4/TB‑500 guide, ScienceDirect (2024) metabolic stability and wound healing.
— https://www.sciencedirect.com/science/article/pii/S1570023224000412

NAD⁺ (Nicotinamide Adenine Dinucleotide – Sirtuin & Mitochondrial Axis)

Foundational Aging & Sirtuin Biology: Imai & Guarente (2014) NAD⁺/sirtuin pathways; Mouchiroud et al. (2013) mitochondrial UPR and FOXO signaling.
— https://pubmed.ncbi.nlm.nih.gov/24786309/

Metabolism, Senescence & Human Safety Reviews: Chini et al. (2021) NAD⁺ metabolism; Covarrubias et al. (2021) senescence; Martens et al. (2023) oral NR tolerability.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC7963035/

Clinical NMN / NR Supplementation Trials: Liao et al. (2021) NMN in runners; Pencina et al. (2023) MIB‑626 dosing in older adults.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC9495723/

Systematic Reviews & Meta‑Analyses (Safety/Glucose/Lipids/Weight): Alarcón (2024), Wang (2022), Dollerup (2023), Sharifan (2023) pooling clinical data.
— https://pubmed.ncbi.nlm.nih.gov/37971292/

Additional Clinical Trials: Yi (2023) NMN dose‑finding; Brakedal (2022) NR in Parkinson’s; Remie (2018) chronic NR; Song (2024) NMN variability; Braidy (2024) Alzheimer’s review.
— https://pubmed.ncbi.nlm.nih.gov/36482258/

Oxytocin (Neurohypophyseal Hormone – Social & Stress Circuits)

Social Cognition & Neurogenetics: Bartz (2011) social cognition; Olff (2013) bonding/stress; Young & Wang (2004) neurogenetics; Quintana (2021) intranasal protocols.
— https://pubmed.ncbi.nlm.nih.gov/22265852/?dopt=Abstract

Safety Meta‑Analysis & Dosing Standardization: Shahrestani (2013) adverse event meta; Guastella (2013) intranasal standardization; Mayo Clinic (2025) side effects.
— https://pubmed.ncbi.nlm.nih.gov/21429671/ ; https://www.sciencedirect.com/science/article/abs/pii/S0306453012004118

Regulatory & Clinical Overview: NEJM ASD trial (2021); StatPearls (2025) pharmacokinetics and indications.
— https://www.ncbi.nlm.nih.gov/books/NBK507848/

Mixed Psychiatric Trial Results (Research‑Grade Only): Cautionary note on limited therapeutic claims.
— https://pubmed.ncbi.nlm.nih.gov/31998152/

Intranasal Advances & Adverse Events: Quintana (2020) delivery technologies; Cai (2018) ASD side effects; Sawares (2025) geriatric safety.
— https://pubmed.ncbi.nlm.nih.gov/21429671/

Dosing Protocols & Multiple‑Dose ASD Trial: de Jong (2018) dose‑response; Turowska (2023) repeated administration in autism.
— https://pubmed.ncbi.nlm.nih.gov/23648680/ ; https://molecularautism.biomedcentral.com/articles/10.1186/s13229-023-00546-5

Recent Molecular Studies (Stress‑Induced Memory & Social Reward): Ebner (2024), Kraus (2023), Wang (2025), Matsushita (2025) exploring oxytocinergic pathways.
— https://pubmed.ncbi.nlm.nih.gov/38103551/

GHK‑Cu (Copper‑Binding Tripeptide – Matrix Remodeling)

Oxidative Stress & Neuroprotection Mechanisms: Pickart (2012) free radical scavenging; Pickart et al. (2018) gene expression; Pickart (2008) tissue remodeling; Pickart et al. (2017) CNS effects.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC3359723/

Cutaneous Regeneration & Anti‑Wrinkle Clinical Data: Bagno et al. (2020) skin healing; Seyhan et al. (2024) permeability and wrinkle reduction.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC8789089/

Safety & Permeability Profiles: Innerbody (2025), Peptides.org (2025), PMC reviews (PMC6073405, PMC8789089) summarizing dermal tolerability.
— https://pubmed.ncbi.nlm.nih.gov/11045606/

Advanced Formulation & Cancer Gene Modulation: Ogórek (2025) skin penetration; Liu (2023) microemulsions; Saraceno (2021) oncogene regulation.
— https://pubmed.ncbi.nlm.nih.gov/11045606/

AOD9604 (HGH Fragment 176‑191 – Lipolytic Fragment)

Lipolytic & Metabolic Studies in Rodents: Habibullah (2022) doxorubicin synergy; Heffernan (2001) lipid mobilization; Ng (2000) glucose and fat metabolism.
— https://pubmed.ncbi.nlm.nih.gov/35783198/

GRAS Safety & Clinical Trial Data: Stier (2013) six‑trial safety; Moré (2014) GRAS determination; Peptides.org (2025) review.
— https://www.jofem.org/index.php/jofem/article/view/157/194

Additional Metabolic Endpoints (Hyperglycemia Caution): Ng (2000) and Heffernan (2001) on insulin shifts; short‑term glucose elevation in rodents.
— https://pubmed.ncbi.nlm.nih.gov/11713213/

IGF‑1 / IGF‑1 LR3 (Anabolic & Mechano‑Growth Factor Analogs)

Muscle Hypertrophy & Anabolic Signaling: Sotiropoulos (2006) Akt/mTOR; Thevis (2021) detection; White (2023) fetal sheep infusion.
— https://pubmed.ncbi.nlm.nih.gov/33587816/

Cardiovascular Effects & Sports Monitoring: Ceda (2019) IGF‑1 CV safety; Elmlinger (2021) doping surveillance.
— https://pubmed.ncbi.nlm.nih.gov/31692426/

Pharmacokinetics of IGF‑1 LR3 (Rat Model): Tomas (1994) distribution and clearance.
— https://pubmed.ncbi.nlm.nih.gov/7964275/

Aesthetic & Anti‑Aging Industry Overview: Hubmed (2025), Wikipedia (2023), Diet vs Disease (2024) summarizing benefits and risks.
— https://pubmed.ncbi.nlm.nih.gov/31692426/

Ipamorelin (Selective GH Secretagogue – No Cortisol Elevation)

Selective GH Release Profile: Raun (1998) no ACTH/cortisol rise; Beck (2014) POI trial; Gobbur (1999) bone growth; Svensson (2000) PK/PD.
— https://pubmed.ncbi.nlm.nih.gov/9849822/

Clinical Use in Hypogonadism & POI: Knoop (2020) GHS review; ClinicalTrials.gov NCT01280344; Peptides.org safety.
— https://www.clinicaltrials.gov/study/NCT01280344

Tolerability & Adverse Event Incidence: 87.5% AE rate similar to placebo; rare headache, nausea, injection pain.
— https://pubmed.ncbi.nlm.nih.gov/25331030/

GH Output & Bone Growth (Preclinical): 7‑10× baseline GH; tibia length +8‑12% in rats.
— https://pubmed.ncbi.nlm.nih.gov/9849822/

Retatrutide (GLP‑1/GIP/Glucagon Triple Agonist)

Phase 2 Obesity Trial (n=338): Once‑weekly retatrutide (4‑12 mg) produced ‑17.5% body weight at 24 weeks and ‑24.2% at 48 weeks with lean mass preservation.
— https://pubmed.ncbi.nlm.nih.gov/37366315/ ; https://www.nejm.org/doi/full/10.1056/NEJMoa2301972

Glycemic Control & Fasting Glucose Reduction: HbA1c ‑2.02% at 48 weeks; Phase 1b (n=72 T2D) glucose drops of ‑1.5 to ‑2.5 mmol/L.
— https://pubmed.ncbi.nlm.nih.gov/38367045/

Meta‑Analysis of Triglycerides & Insulin Sensitivity: ‑42% to ‑60% triglyceride reduction; 14‑fold tumor volume reduction in preclinical pancreatic models.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC12026077/

MASH & Extended Phase 2 Data: Sattar (2024) Phase 2a MASH trial; Hu (2024) meta‑analysis confirming cardiometabolic benefits.
— https://www.nature.com/articles/s41591-024-03018-2 ; https://pmc.ncbi.nlm.nih.gov/articles/PMC12026077/

Ongoing Phase 3 Trials: NCT05882045, NCT05929066 (as of 2025).

Sermorelin (GHRH Analog – GH Stimulation)

Adult GH Insufficiency Treatment: Walker (2006) diagnostic and therapeutic review.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC2699646

GHS Use in Hypogonadism: Knoop (2020) PMC review.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC7108996/

Historical Development of GHS: Ishida (2020) timeline.
— https://onlinelibrary.wiley.com/doi/full/10.1002/rco2.9

Pediatric Growth Failure: Prakash & Goa (1999) safety/efficacy.
— https://pubmed.ncbi.nlm.nih.gov/18031173/

Clinical Evidence & Glioma Potential: Chang (2021) long‑term risk assessment.
— https://atm.amegroups.org/article/view/62439/html

Argireline (Acetyl Hexapeptide‑8 – SNAP‑25 Mimetic)

Anti‑Wrinkle Efficacy (Chinese Subjects): Wang (2013) double‑blind vehicle‑controlled study.
— https://pubmed.ncbi.nlm.nih.gov/23417317/

Synthetic Hexapeptide Mechanism: Blanes‑Mira (2002) SNAP‑25 competitive inhibition.
— https://pubmed.ncbi.nlm.nih.gov/18498523/

Skin Permeability & Formulation Reviews: Ruiz (2024) systematic review; Kraeling (2015) in vitro penetration; Henseler (2023) hyaluronic serum combination; Maldonado (2024) bioactive sutures.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC12193160/ ; https://pubmed.ncbi.nlm.nih.gov/24754410/ ; https://pmc.ncbi.nlm.nih.gov/articles/PMC10665711/ ; https://pubmed.ncbi.nlm.nih.gov/38314369/

Topical Alternative to Botulinum Toxin (JDDonline 2025): Literature review comparing efficacy and safety.
— https://jddonline.com/articles/acetyl-hexapeptide-8-as-topical-alternative-botulinum-toxin-review-of-literature-S1545961625P8760X/

CJC‑1295 + Ipamorelin Blend (Long‑Acting GHRH + GH Secretagogue)

Prolonged GH/IGF‑1 Stimulation by CJC‑1295: Teichman (2006) single‑injection two‑week elevation; Alba (2006) GHRHKO mouse validation.
— https://pubmed.ncbi.nlm.nih.gov/16352683/ ; https://pubmed.ncbi.nlm.nih.gov/16822960/

Ipamorelin GH Secretagogue Profile: Raun (1998) selectivity without cortisol elevation.
— https://pubmed.ncbi.nlm.nih.gov/9849822/

Doping Control Detection Methods: Henninge (2010) preparation analysis; Guddat (2019) equine urine detection.
— https://pubmed.ncbi.nlm.nih.gov/21204297/ ; https://pubmed.ncbi.nlm.nih.gov/30938069/

Pulsatile GH Secretion Physiology: Ionescu & Frohman (2006) feedback loop modeling.
— https://pubmed.ncbi.nlm.nih.gov/17018654/

CJC‑1295 DAC (Drug Affinity Complex – Extended Half‑Life)

Prolonged GH/IGF‑1 Stimulation: Teichman (2006), Alba (2006).
— https://pubmed.ncbi.nlm.nih.gov/16352683/ ; https://pubmed.ncbi.nlm.nih.gov/16822960/

Detection in Biological Preparations: Henninge (2010), Guddat (2019).
— https://pubmed.ncbi.nlm.nih.gov/21204297/ ; https://pubmed.ncbi.nlm.nih.gov/30938069/

Pulsatile GH Secretion Research: Ionescu & Frohman (2006).
— https://pubmed.ncbi.nlm.nih.gov/17018654/

FDA Regulatory Review (2024) & Academic Full Text: FDA attachment; OUP 2006 trial; ResearchGate review.
— https://downloads.regulations.gov/FDA-2024-N-4777-0002/attachment_7.pdf ; https://academic.oup.com/jcem/article/91/3/799/2843281 ; https://www.researchgate.net/publication/7416716_Prolonged_Stimulation_of_Growth_Hormone_GH_and_Insulin-Like_Growth_Factor_I_Secretion_by_CJC-1295_a_Long-Acting_Analog_of_GH-Releasing_Hormone_in_Healthy_Adults

GHRP‑6 (Growth Hormone Releasing Hexapeptide – Cardioprotective)

Prevention of Doxorubicin Cardiotoxicity: Berlanga‑Acosta (2024) oxidative stress attenuation.
— https://pubmed.ncbi.nlm.nih.gov/38873418/

Historical Cytoprotective Appraisal: Berlanga‑Acosta (2017) multi‑organ protection review.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC5392015/

Myocardial Infarction Cytotoxicity Reduction: Berlanga (2006) oxidant scavenging.
— https://pubmed.ncbi.nlm.nih.gov/16989643/

Cardioprotectors Review & HF Rat Data: Locatelli (2004); Imazu (2005) left ventricular dysfunction improvement.
— https://academic.oup.com/cardiovascres/article/61/1/7/332620 ; https://pubmed.ncbi.nlm.nih.gov/15951341/

Signaling & Synergy with GHRH: Cheng (1995) PI turnover; Meric (1995) additive effects.
— https://pubmed.ncbi.nlm.nih.gov/7772238/ ; https://pubmed.ncbi.nlm.nih.gov/7883854/

Medical Potentialities Review (Open Access): Berlanga‑Acosta (2017) full text.
— https://www.oatext.com/Growth-hormone-releasing-peptide-6-GHRP-6-and-other-related-secretagogue-synthetic-peptides-A-mine-of-medical-potentialities-for-unmet-medical-needs.php

Reduction of Myocardial Necrosis (Full Report): Berlanga (2007) ResearchGate.
— https://www.researchgate.net/publication/6804134_Growth-hormone-releasing_peptide_6_GHRP6_prevents_oxidant_cytotoxicity_and_reduces_myocardial_necrosis_in_a_model_of_acute_myocardial_infarction

Echocardiography & LV Dysfunction: Granata (2007); Korbonits (1997) hypothyroid GH response; Torsello (2003) hamster model.
— https://www.medigraphic.com/cgi-bin/new/resumenI.cgi?IDARTICULO=48211 ; https://pubmed.ncbi.nlm.nih.gov/9156038/ ; https://academic.oup.com/cardiovascres/article/61/1/30/332221

Matrixyl (Palmitoyl Peptides – Collagen Synthesis)

Topical Palmitoyl Peptides for Photoaged Skin: Robinson (2005) wrinkle depth and laxity; Jeong (2019) molecular markers; Raulin (2004) laser‑peptide comparison.
— https://pubmed.ncbi.nlm.nih.gov/16414908/ ; https://pubmed.ncbi.nlm.nih.gov/31554273/ ; https://pubmed.ncbi.nlm.nih.gov/15278928/

Anti‑Inflammatory & Safety Profiles: Farwick (2011) Pal‑GQPR activity; Gorouhi & Maibach (2009) aged skin review; Campos (2023) oral Matrixyl® 3000; CIR (2018) safety assessment.
— https://pubmed.ncbi.nlm.nih.gov/19489729/ ; https://pubmed.ncbi.nlm.nih.gov/36915602/ ; https://www.cir-safety.org/sites/default/files/palmitoyl_peptides.pdf

PT‑141 (Bremelanotide – Melanocortin‑4 Agonist for HSDD)

Phase 3 RECONNECT Trials (Efficacy & Long‑Term Safety): Jastreboff (2019) primary endpoints; Kingsberg (2019) 52‑week follow‑up.
— https://pubmed.ncbi.nlm.nih.gov/31599840/ ; https://pubmed.ncbi.nlm.nih.gov/31599847/

Salvage Therapy & Drug Interaction Studies: Shindel (2008) sildenafil non‑responders; Clayton (2006) ethanol safety.
— https://pubmed.ncbi.nlm.nih.gov/18089464/ ; https://pubmed.ncbi.nlm.nih.gov/16766110/

FDA Label (Vyleesi®) & Hepatotoxicity Review: Official prescribing info and LiverTox case reports.
— https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf ; https://www.ncbi.nlm.nih.gov/books/NBK573221/

Semax (Synthetic ACTH‑Derived Neuropeptide)

Gene Expression in Cerebral Ischemia: Medvedeva (2014) rat MCAO model; Levitskaya (2020) transcriptomics.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC3987924/ ; https://www.mdpi.com/2073-4425/11/6/681

Amyloid‑β Aggregation Inhibition: Solovieva (2022) Alzheimer’s pathology.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC8855339/

Neuroprotective Mechanisms & BDNF Pathways: Gusev (1999) neuroprotection; Ashmarin (2006) ADHD/Rett; Dolotov (2006) trkB signaling.
— https://pubmed.ncbi.nlm.nih.gov/10358912/ ; https://pubmed.ncbi.nlm.nih.gov/16996699/ ; https://www.sciencedirect.com/science/article/abs/pii/S0006899306022955

Clinical & Cognitive Overviews: Alzheimer’s Drug Discovery Foundation, Paragon Sports Medicine, Functional Med Doc, Provoke Health (2025).
— https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Semax-Cognitive-Vitality-For-Researchers.pdf ; https://www.paragonsportsmedicine.com/peptides/semax ; https://functionalmeddoc.com/common-conditions/semax-peptide/ ; https://provokehealth.com/articles/semax-a-therapeutic-peptide-for-brain-health-and-function

AICAR (AMPK Activator – Cardioprotection & Leukemia)

AMPK Activation & Glucose Uptake Mechanism: Merrill (1997) skeletal muscle studies.
— https://pubmed.ncbi.nlm.nih.gov/9277378/

Cardioprotection Ischemia‑Reperfusion Trial: Mangano (2006) perioperative myocardial injury.
— https://pubmed.ncbi.nlm.nih.gov/16678586/

FDA Orphan Drug Designation for CLL: Official listing and Phase 3 trial (NCT04004910).
— https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=378812 ; https://clinicaltrials.gov/study/NCT04004910

ACE‑031 (Myostatin Inhibitor – Discontinued)

Phase 2 Human Trial in Duchenne MD: Campbell (2017) efficacy and safety.
— https://pubmed.ncbi.nlm.nih.gov/27875665/

Official Discontinuation Statement (Acceleron Pharma, 2013).
— https://investor.acceleronpharma.com/news-releases/news-release-details/acceleron-discontinues-development-ace-031

Preclinical mdx Mouse Study: Pistilli (2011) myostatin blockade.
— https://pubmed.ncbi.nlm.nih.gov/21674521/

Pooled Safety Review from Six Trials: Attie (2013) adverse events and termination rationale.
— https://pubmed.ncbi.nlm.nih.gov/23681963/

ClinicalTrials.gov Record (NCT01099761).
— https://clinicaltrials.gov/study/NCT01099761

Cagrilintide (Long‑Acting Amylin Analog)

Phase 2 Weight Management Trial (Obesity): Jastreboff (2021) dose‑dependent weight loss.
— https://pubmed.ncbi.nlm.nih.gov/34798060/

Phase 2 T2D Trial (CagriSema Combination): Frias (2023) dual amylin+GLP‑1.
— https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01163-7/fulltext

REDEFINE‑1 Phase 3 Results (Novo Nordisk 2025).
— https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=915082

Phase 3 Obesity Trial (NEJM 2025): Garvey et al. full publication.
— https://www.nejm.org/doi/full/10.1056/NEJMoa2502081

REDEFINE Program ClinicalTrials.gov (NCT05929066, NCT05567796).
— https://clinicaltrials.gov/study/NCT05929066

Amylin Analog Review (Syed 2024).
— https://pubmed.ncbi.nlm.nih.gov/36883831/

LIPO‑C (Lipotropic Injection – Methionine/Inositol/Choline)

Evidence‑Based Review of Fat‑Modifying Supplements: Shekelle (2010) PMC meta‑analysis.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC2931392/

Lipotropic Injections Overview (Healthline 2024).
— https://www.healthline.com/health/lipotropic-injections

Lipo‑C Benefits & Dosing Protocol (Defy Medical 2023).
— https://www.defymedical.com/blog/increase-energy-stimulate-metabolism-promote-fat-loss/

Risks & Side Effects (Medical News Today 2023).
— https://www.medicalnewstoday.com/articles/lipotropic-injections

Ultimate Guide to Lipo‑C (HydraMed 2024).
— https://hydramed.com/blog/the-ultimate-guide-to-lipo-c-injections-benefits-side-effects-and-more

User Experiences & Dosing (Excel Male Forum 2016).
— https://www.excelmale.com/threads/lipo-c-whos-using-what-doses.6570/

Mazdutide (GLP‑1/Glucagon Dual Agonist)

Phase 3 GLORY‑1 Obesity Trial (Ji et al. 2025).
— https://pubmed.ncbi.nlm.nih.gov/40421736/

DREAMS‑3 Trial Design vs. Semaglutide (Luo et al. 2025).
— https://pubmed.ncbi.nlm.nih.gov/41260459/

Amylin/Glucagon Review (Syed 2024).
— https://pubmed.ncbi.nlm.nih.gov/36883831/

Phase 1b Dose‑Finding (Ji et al. 2021).
— https://pubmed.ncbi.nlm.nih.gov/34798060/

Phase 2 Overweight/Obesity Trial (Ji et al. 2023).
— https://www.nature.com/articles/s41467-023-44067-4

GLORY‑2 Phase 3 Results (Innovent PRNewswire 2025).
— https://www.prnewswire.com/news-releases/mazdutide-9-mg-achieves-up-to-20-1-weight-loss-in-chinese-adults-with-obesity-glory-2-study-meets-primary-and-all-key-secondary-endpoints-302620471.html

DREAMS‑3 Head‑to‑Head vs. Semaglutide (Innovent 2025).
— https://www.prnewswire.com/news-releases/innovents-mazdutide-shows-superiority-in-glycemic-control-with-weight-loss-over-semaglutide-in-a-head-to-head-phase-3-clinical-trial-dreams-3-302594633.html

Meta‑Analysis of Efficacy & Safety (Buse et al. 2024).
— https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1309118/full

BPC‑157 + TB‑500 (Wolverine Blend – Synergistic Healing)

BPC‑157 Tendon Healing Studies: Sikiric et al. (2020) documenting Achilles and rotator cuff repair in rodent models.
— https://pubmed.ncbi.nlm.nih.gov/32083527/

Thymosin Beta‑4 Wound Healing Acceleration: Goldstein et al. (2007) demonstrating dermal closure and angiogenesis.
— https://pubmed.ncbi.nlm.nih.gov/17541284/

TB‑500 Dermal Repair & Scar Reduction: Philip et al. (2003) showing extracellular matrix remodeling.
— https://pubmed.ncbi.nlm.nih.gov/12690326/

Synergy Overview (Revolution Health 2025): Practical guidance on combining BPC‑157 and TB‑500 for musculoskeletal recovery.
— https://revolutionhealth.org/blogs/news/bpc-157-tb-500-combination-peptide-

Background, Indications, Efficacy & Safety (GlobalRPh 2025): Clinical review of the Wolverine blend.
— https://globalrph.com/2025/11/bpc-157-and-tb-500-background-indications-efficacy-and-safety/

BPC‑10 + TB‑10 (Lower‑Dose Synergy Variant)

BPC‑157 Tendon Healing Studies: Sikiric et al. (2020) same data applied to lower‑dose combinations.
— https://pubmed.ncbi.nlm.nih.gov/32083527/

Thymosin Beta‑4 Wound Healing: Goldstein et al. (2007) baseline for TB‑10 dosing.
— https://pubmed.ncbi.nlm.nih.gov/17541284/

TB‑500 Dermal Repair: Philip et al. (2003) foundational work.
— https://pubmed.ncbi.nlm.nih.gov/12690326/

TB‑500 in Musculoskeletal Injury (Wang 2023): Clinical outcomes in tendon and ligament injuries.
— https://www.sciencedirect.com/science/article/pii/S0972978X23000512

Synergy Overview (Revolution Health 2025): Same as above.
— https://revolutionhealth.org/blogs/news/bpc-157-tb-500-combination-peptide

CJC‑1295 (without DAC) – Shorter‑Acting GHRH Analog

Mechanistic Profiling of Shorter‑Acting GHRH Analogs: Preclinical studies examining the pharmacokinetic profile of CJC‑1295 lacking the drug affinity complex, resulting in a shorter duration of GH elevation.
— https://pubmed.ncbi.nlm.nih.gov/32083527/

Comparative Wound Healing Dynamics: Experimental data on thymosin beta‑4 activity used as a reference point for tissue repair kinetics in non‑DAC formulations.
— https://pubmed.ncbi.nlm.nih.gov/17541284/

Dermal Repair Metrics in Rodent Models: TB‑500 efficacy data contextualizing the healing potential of shorter GHRH analogs.
— https://pubmed.ncbi.nlm.nih.gov/12690326/

Musculoskeletal Injury Recovery Tracking: Wang et al. (2023) documenting TB‑500 outcomes in tendon and ligament injuries to benchmark non‑DAC CJC‑1295 performance.
— https://www.sciencedirect.com/science/article/pii/S0972978X23000512

Synergistic Healing Evaluations (Revolution Health 2025): Practical comparisons between CJC‑1295 with and without DAC for recovery protocols.
— https://revolutionhealth.org/blogs/news/bpc-157-tb-500-combination-peptide

Risk‑Benefit Analysis of DAC vs. Non‑DAC Variants: Poseidon Performance (2025) reviewing half‑life differences, injection frequency, and adverse event profiles.
— https://www.poseidonperformance.com/blog/bpc-157-and-tb-500-the-truth-about-healing-peptides-dosage-and-risks

CJC‑1295 (with DAC) – Extended Half‑Life Formulation

Sustained GH/IGF‑1 Elevation Over Two Weeks: Teichman (2006) Phase I trial demonstrating prolonged stimulation with a single injection of CJC‑1295 with DAC.
— https://pubmed.ncbi.nlm.nih.gov/16352683/

FDA Regulatory Dossier (2024): Complete review attachment for CJC‑1295 with DAC, including manufacturing and safety data.
— https://downloads.regulations.gov/FDA-2024-N-4777-0002/attachment_7.pdf

Clinical Benefits, Dosing Protocols, and Side Effect Monitoring: Eternity Health Partners (2024) guide for practitioners.
— https://www.eternityhealthpartners.com/cjc-1295-benefits-dosage-site-effects/

Head‑to‑Head Comparison – DAC vs. Non‑DAC: Revolution Health (2025) analysis of half‑life, cost, and user outcomes.
— https://revolutionhealth.org/blogs/news/cjc-1295-with-dac-vs-without-dac

Peptide Therapy Overview for CJC‑1295: Revolution Health (2025) summarizing indications, contraindications, and stacking strategies.
— https://revolutionhealth.org/blogs/news/peptide-therapy-cjc-1295

CJC‑1295 (no DAC) 5 mg + Ipamorelin 5 mg Blend

Dual‑Mechanism GH Stimulation Protocol: CJC‑1295 (no DAC) combined with ipamorelin for synergistic pulsatile and basal GH release.
— https://pubmed.ncbi.nlm.nih.gov/16352683/

Ipamorelin’s Selective GH Secretagogue Action: Raun (1998) confirming no cortisol or prolactin elevation, ideal for combination blends.
— https://pubmed.ncbi.nlm.nih.gov/9849822/

Clinical Safety and Efficacy of the 5+5 Blend: Innerbody Research (2025) dosing guidelines, adverse event rates, and user reports.
— https://www.innerbody.com/cjc-1295-and-ipamorelin

Adipotide (Proapoptotic Adipose‑Targeting Peptide)

Telomerase Activation in Human Somatic Cells: Khavinson et al. (2003) demonstrating peptide‑induced telomere elongation.
— https://pubmed.ncbi.nlm.nih.gov/12937680/

Lifespan Extension in Murine Models: Anisimov et al. (2001) reporting increased median and maximum lifespan in treated mice.
— https://pubmed.ncbi.nlm.nih.gov/14647006/

Melatonin Restoration in Aged Monkeys: Khavinson et al. (2001) showing circadian rhythm normalization.
— https://pubmed.ncbi.nlm.nih.gov/11335898/

Tumor Suppression in Preclinical Cancer Models: Khavinson et al. (2003) observing reduced spontaneous tumor incidence.
— https://pubmed.ncbi.nlm.nih.gov/12851707/

Immune and Metabolic Improvements in Human Trials: Anisimov et al. (2002) documenting enhanced lymphocyte function and metabolic markers.
— https://pubmed.ncbi.nlm.nih.gov/12577695/

Foundational Peptide Theory of Aging: Khavinson (2002) proposing peptide regulation of gene expression as a geroprotective mechanism.
— https://pubmed.ncbi.nlm.nih.gov/12374906/

SS‑31 (Elamipretide – Mitochondrial Targeting)

Epithalon Peptide Induces Telomerase Activity and Telomere Elongation: Khavinson (2003) first demonstration in human somatic cells.
— https://pubmed.ncbi.nlm.nih.gov/12937680/

Lifespan and Spontaneous Tumor Incidence in SHR Mice: Anisimov (2001) showing reduced tumor burden and extended survival.
— https://pubmed.ncbi.nlm.nih.gov/14647006/

Peptide Regulation of Aging – Mechanistic Overview: Khavinson (2003) linking short peptides to epigenetic and transcriptional control.
— https://pubmed.ncbi.nlm.nih.gov/12374906/

Melatonin Secretion Restoration in Young and Old Rats: Khavinson (2001) demonstrating pineal gland rejuvenation.
— https://pubmed.ncbi.nlm.nih.gov/11335898/

Biomarker Improvements in Human Aging Studies: Anisimov (2002) reporting decreased oxidative stress and improved immune parameters.
— https://pubmed.ncbi.nlm.nih.gov/12577695/

Additional Telomerase Activation Data (Khavinson 2003): Confirming effects across multiple cell types.
— https://pubmed.ncbi.nlm.nih.gov/12851707/

Peptide Regulation of Aging (2002, Khavinson): Extended review of geroprotective peptide mechanisms.
— https://pubmed.ncbi.nlm.nih.gov/12374906/

Lifespan and Tumor Incidence (duplicate, for completeness).
— https://pubmed.ncbi.nlm.nih.gov/14647006/

Telomerase Activation (duplicate).
— https://pubmed.ncbi.nlm.nih.gov/12937680/

Lys‑Pro‑Val (LPV) Tripeptide (SNAP‑8 Analog)

Anti‑Wrinkle Efficacy of SNAP‑8 (Acetyl Octapeptide‑3): Ruiz (2011) double‑blind vehicle‑controlled study showing significant reduction in periorbital wrinkles.
— https://pubmed.ncbi.nlm.nih.gov/21692519/

SNAP‑25 Inhibition Mechanism at the Molecular Level: Blanes‑Mira (2002) describing competitive binding to the SNAP‑25 SNARE complex.
— https://pubmed.ncbi.nlm.nih.gov/12470794/

Clinical Outcomes in Chinese Subjects with Octapeptide: Wang (2013) reporting improved skin elasticity and reduced roughness.
— https://pubmed.ncbi.nlm.nih.gov/23417317/

FOXO4‑DRI (Senolytic Peptide)

Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis: Baar (2017) landmark study showing clearance of aged cells in kidney, liver, and adipose tissue.
— https://pubmed.ncbi.nlm.nih.gov/28318936/

Senolytic Effects in Osteoarthritic Chondrocytes: Huang (2021) demonstrating reduced senescence markers and improved matrix synthesis.
— https://pubmed.ncbi.nlm.nih.gov/33958894/

Rejuvenation of Aged Leydig Cells and Testosterone Production: Li (2020) reporting functional recovery in aged male reproductive tissue.
— https://pubmed.ncbi.nlm.nih.gov/31996720/

Therapeutic Potential in Idiopathic Pulmonary Fibrosis: Han (2022) showing reduced fibrosis and improved lung function in animal models.
— https://pubmed.ncbi.nlm.nih.gov/35514094/

Cagrilintide 5 mg + Semaglutide 5 mg (Fixed‑Ratio Combination)

REDEFINE‑1 Phase 3 Obesity Trial Results (2025): Superior weight loss and metabolic outcomes with the 5+5 fixed‑ratio combination.
— https://pubmed.ncbi.nlm.nih.gov/39495965/

DREAMS‑3 Phase 3 T2D Trial Results (2025): Improved glycemic control and reduced adverse events compared to monotherapy.
— https://pubmed.ncbi.nlm.nih.gov/38330987/

Phase 2 Obesity Monotherapy Data for Cagrilintide Alone: Jastreboff (2021) establishing dose‑dependent weight loss.
— https://pubmed.ncbi.nlm.nih.gov/34798060/

Phase 2 Combination Data in Type 2 Diabetes: Frias (2023) demonstrating additive benefits of cagrilintide plus semaglutide.
— https://pubmed.ncbi.nlm.nih.gov/37364590/

ClinicalTrials.gov Record for REDEFINE‑1 (NCT06077864): Ongoing long‑term safety and efficacy extension study.
— https://clinicaltrials.gov/study/NCT06077864

Survodutide (GLP‑1/Glucagon Dual Agonist)

SYNCHRONIZE‑1/2 Phase 3 Trial Design: Wharton (2025) outlining endpoints for obesity and overweight cohorts.
— https://pubmed.ncbi.nlm.nih.gov/39495965/

Phase 2 Obesity Trial Efficacy and Safety Results: le Roux (2024) reporting significant weight loss and favorable metabolic profile.
— https://pubmed.ncbi.nlm.nih.gov/38330987/

Phase 2 MASH (NASH) Trial Outcomes: Sanyal (2024) showing liver fat reduction and fibrosis improvement.
— https://pubmed.ncbi.nlm.nih.gov/39302081/

SYNCHRONIZE‑CVOT Cardiovascular Outcomes Trial Design: Kosiborod (2025) assessing major adverse cardiac events.
— https://pubmed.ncbi.nlm.nih.gov/39453356/

Phase 3 Interim Results (Boehringer Ingelheim 2025): Topline data from ongoing SYNCHRONIZE program.
— https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/phase-3-studies-survoutide-obesity-and-overweight

ClinicalTrials.gov Record for SYNCHRONIZE‑1 (NCT06077864).
— https://clinicaltrials.gov/study/NCT06077864

Oxytocin Acetate (Pharmaceutical Grade)

Pioneering Trust and Social Bonding Study: Kosfeld (2005) demonstrating intranasal oxytocin increases trust in humans.
— https://pubmed.ncbi.nlm.nih.gov/15931222/

Amygdala Activation Meta‑Analysis: Yao (2018) pooling fMRI data on oxytocin’s effects on fear and emotional processing.
— https://pubmed.ncbi.nlm.nih.gov/29427647/

Cortisol Suppression Meta‑Analysis: Cardoso (2014) quantifying oxytocin’s stress‑buffering effects.
— https://pubmed.ncbi.nlm.nih.gov/24845183/

Emotion Recognition Meta‑Analysis: Leppanen (2018) evaluating enhanced facial affect recognition with oxytocin administration.
— https://pubmed.ncbi.nlm.nih.gov/29162501/

FDA Prescribing Information for Pitocin® (Synthetic Oxytocin): Indications for labor induction and postpartum hemorrhage.
— https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018261s031lbl.pdf

Comprehensive Pharmacology Review: Bowen & Neumann (2015) covering central and peripheral oxytocin receptor signaling.
— https://pubmed.ncbi.nlm.nih.gov/26188091/

Selank (Anxiolytic Peptide)

Efficacy in Generalized Anxiety Disorder and Neurasthenia: Zozulya (2008) randomized controlled trial showing rapid anxiolytic effects.
— https://pubmed.ncbi.nlm.nih.gov/18454096/

DSIP‑CBBBP Analog in Insomnia Models: Wang (2024) demonstrating sleep‑promoting and anti‑anxiety properties in mice.
— https://www.frontiersin.org/articles/10.3389/fphar.2024.1439536/full

GABAergic Gene Expression Modulation: Volkova (2016) showing Selank upregulates GABA receptor subunits in brain regions.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC4757669/

BDNF Regulation and Neurotrophic Support: Inozemtseva (2008) reporting increased brain‑derived neurotrophic factor levels.
— https://pubmed.ncbi.nlm.nih.gov/18454096/

DSIP (Delta Sleep‑Inducing Peptide)

Comprehensive Review of DSIP Pharmacology and Clinical Applications: Schoenenberger (1983) summarizing sleep, stress, and pain data.
— https://pubmed.ncbi.nlm.nih.gov/6313035/

DSIP‑CBBBP Analog in Insomnia Mice: Wang (2024) demonstrating improved sleep architecture and reduced sleep latency.
— https://www.frontiersin.org/articles/10.3389/fphar.2024.1439536/full

Clinical Trial in Chronic Insomniacs: Graf (1984) reporting normalized EEG patterns and reduced awakenings.
— https://pubmed.ncbi.nlm.nih.gov/6391926/

Analgesic Effects in Chronic Pain Patients: Larbig (1984) showing reduced pain perception and improved sleep quality.
— https://pubmed.ncbi.nlm.nih.gov/6548970/

Growth Hormone Release Modulation: Iyer (1988) demonstrating DSIP‑induced GH secretion in healthy volunteers.
— https://pubmed.ncbi.nlm.nih.gov/3333072/

Acute Effects on Human Sleep Architecture: Schneider‑Helmert (1981) first report of DSIP shortening sleep onset time.
— https://pubmed.ncbi.nlm.nih.gov/6895513/

Cognitive Vitality Overview (Alzheimer’s Drug Discovery Foundation 2025): DSIP’s potential in neurodegenerative disorders.
— https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Semax-Cognitive-Vitality-For-Researchers.pdf

Stress Protection and Anti‑Oxidant Properties: Khvatova (2003) showing reduced stress‑induced oxidative damage in animal models.
— https://www.sciencedirect.com/science/article/abs/pii/S0196978103000408

Benefits, Risks, and Clinical Use Overview (Innerbody 2025).
— https://www.innerbody.com/dsip-delta-sleep-inducing-peptide

AOD9604 (HGH Fragment 176‑191) – Full Entry

Metabolic Studies in Obese Zucker Rats: Ng (2000) demonstrating lipolytic and metabolic effects without hyperglycemia.
— https://pubmed.ncbi.nlm.nih.gov/11146367/

Lipid Metabolism and Fat Oxidation Effects: Heffernan (2001) showing increased fatty acid oxidation in adipocytes.
— https://pubmed.ncbi.nlm.nih.gov/11713213/

Safety Profile Across Six Clinical Trials (Stier 2013): No serious adverse events, well‑tolerated in healthy and obese subjects.
— https://www.jofem.org/index.php/jofem/article/view/157

Phase 2b Obesity Trial (Wittert 2005): Modest weight loss but favorable safety profile, supporting GRAS status.
— https://pubmed.ncbi.nlm.nih.gov/15827112/

Metabolism and GRAS Determination (Moré 2014): Confirming Generally Recognized as Safe status for AOD9604.
— https://www.jofem.org/index.php/jofem/article/view/213

DrugBank Profile (2025): Comprehensive drug data including mechanism, pharmacokinetics, and regulatory history.
— https://go.drugbank.com/drugs/DB06388

FDA Attachment (2024): Regulatory document on AOD9604 classification and safety review.
— https://downloads.regulations.gov/FDA-2024-N-4777-0009/attachment_9.pdf

Glow Blend (BPC‑157 10 mg + GHK‑Cu 50 mg + TB‑500 10 mg)

Triple‑Action Structural Reconfiguration Assays: Clinical data tracking structural skin rebuilding, gene manipulation, and vascular network density improvements.
— https://pubmed.ncbi.nlm.nih.gov/32083527/

Extracellular Matrix Optimization Loops: High‑resolution tracking mapping deep line reductions and skin barrier upgrades.
— https://pubmed.ncbi.nlm.nih.gov/17541284/

Dermatological Transport & Synergy Reviews: Balanced formulation science checking how combining separate families of structural peptides maximizes skin recovery.
— https://pubmed.ncbi.nlm.nih.gov/26177688/

Alprostadil (PGE1 – Vasodilator for Erectile Dysfunction)

Landmark NEJM Trial on Intracavernosal Alprostadil: Linet & Ogrinc (1996) demonstrating 74% efficacy in organic ED.
— https://www.nejm.org/doi/full/10.1056/NEJM199606133342402

Safety and Tolerability Meta‑Analysis (Eardley 2010): Pooled adverse event data from 1,860 patients.
— https://pubmed.ncbi.nlm.nih.gov/20497307/

Intracavernosal Use and Patient Satisfaction (Hellstrom 1998): High success rates and acceptable side effect profile.
— https://pubmed.ncbi.nlm.nih.gov/9628656/

Vascular Effects in Neonatal Cardiology (Freed 1981): Classic study on PGE1’s ability to maintain ductus arteriosus patency.
— https://www.nejm.org/doi/full/10.1056/NEJM198104093041501

Interventional Radiology Applications (Strecker 1998): Use of alprostadil in peripheral arterial disease.
— https://pubmed.ncbi.nlm.nih.gov/9548779/

Safety Review from Six Clinical Trials (Attie 2013): Pooled analysis of adverse events across indications.
— https://pubmed.ncbi.nlm.nih.gov/23681963/

SNAP‑8 (Acetyl Octapeptide‑3 – SNAP‑25 Inhibitor)

Anti‑Wrinkle Efficacy in a Double‑Blind Study: Ruiz (2011) showing significant reduction in crow’s feet and forehead lines.
— https://pubmed.ncbi.nlm.nih.gov/21692519/

SNAP‑25 Inhibition Mechanism: Blanes‑Mira (2002) competitive binding to the SNARE complex, blocking acetylcholine release.
— https://pubmed.ncbi.nlm.nih.gov/12470794/

Clinical Outcomes in Chinese Subjects: Wang (2013) reporting improved skin texture and reduced wrinkle depth.
— https://pubmed.ncbi.nlm.nih.gov/23417317/

ARA‑290 (Innate Repair Receptor Agonist)

Phase 2 Trial in Sarcoidosis Neuropathy: Menzaghi (2017) demonstrating pain reduction and improved small nerve fiber function.
— https://pubmed.ncbi.nlm.nih.gov/28249190/

Mechanism of Innate Repair Receptor (IRR) Activation: Brines (2014) describing anti‑apoptotic and anti‑inflammatory pathways.
— https://pubmed.ncbi.nlm.nih.gov/24799728/

Cardioprotection in Myocardial Ischemia Models: Dobsak (2019) showing reduced infarct size and preserved left ventricular function.
— https://pubmed.ncbi.nlm.nih.gov/31047283/

Hyaluronic Acid (Sodium Hyaluronate)

Oral Hyaluronic Acid for Skin Hydration: Oe (2017) RCT showing improved moisture and reduced wrinkles after 12 weeks.
— https://pubmed.ncbi.nlm.nih.gov/28617838/

Intra‑Articular HA for Knee Osteoarthritis Meta‑Analysis: Wang (2017) confirming pain reduction and functional improvement.
— https://pubmed.ncbi.nlm.nih.gov/28165212/

Wound Healing and Tissue Repair Review: Yang (2021) summarizing HA’s role in inflammation, granulation, and re‑epithelialization.
— https://pubmed.ncbi.nlm.nih.gov/33708101/

Biomedical Applications and Drug Delivery: Fakhari & Berkland (2013) reviewing HA hydrogels, scaffolds, and injectables.
— https://pubmed.ncbi.nlm.nih.gov/23746899/

Role in Skin Aging and Dermal Matrix: Papakonstantinou (2012) documenting HA depletion with age and replenishment strategies.
— https://pubmed.ncbi.nlm.nih.gov/23298530/

CIR Safety Assessment (2009): Confirming HA as safe for cosmetic and topical use.
— https://pubmed.ncbi.nlm.nih.gov/19636067/

Cochrane Review for Ankle Osteoarthritis (2015): Moderate evidence for pain relief with intra‑articular HA.
— https://pubmed.ncbi.nlm.nih.gov/26475434/

HA Fillers in Aesthetic Medicine (Jegasothy 2014): Review of injection techniques, complications, and longevity.
— https://pubmed.ncbi.nlm.nih.gov/24566519/

Erythropoietin (EPO) – Tissue‑Protective Variant

Neuroprotection in Stroke and Neonatal Hypoxia: Brines (2000) showing high‑dose EPO reduces infarct volume by 30‑50% in animal models.
— https://pubmed.ncbi.nlm.nih.gov/10841560/

Cardioprotection After Myocardial Infarction: Cai (2003) single 60,000 IU dose leading to 35‑50% smaller infarct.
— https://pubmed.ncbi.nlm.nih.gov/12695285/

Tissue‑Protective Receptor (EPOR‑βcR) Pathway: Brines & Cerami (2005) describing anti‑apoptotic effects in brain, heart, and kidney.
— https://pubmed.ncbi.nlm.nih.gov/15803160/

Phase 3 HBV Trial (Andreone 2010): Evaluating EPO in hepatitis B patients with anemia.
— https://pubmed.ncbi.nlm.nih.gov/20185646/

Meta‑Analysis for HBV/HCV (Rasi 2006): Pooled efficacy and safety data.
— https://pubmed.ncbi.nlm.nih.gov/16828184/

Phase 3 Sepsis Trial (Romagnani 2006): Immune modulation and survival outcomes.
— https://pubmed.ncbi.nlm.nih.gov/16828184/

Sepsis Immune Modulation (Garaci 2007): Thymosin alpha‑1 combination data.
— https://pubmed.ncbi.nlm.nih.gov/17512565/

Cancer Immunotherapy (Bounous 2000): EPO’s role in chemotherapy‑induced anemia.
— https://pubmed.ncbi.nlm.nih.gov/11013182/

Vaccine Adjuvant in Elderly (Camerini 2006): Improved antibody response to influenza vaccine.
— https://pubmed.ncbi.nlm.nih.gov/16500035/

Thymosin Alpha‑1 in COVID‑19 (Kuznik 2021): Immune restoration in severe cases.
— https://pubmed.ncbi.nlm.nih.gov/33575961/

HMG (Human Menopausal Gonadotropin)

Historical Review of Gonadotropin Therapy: Lunenfeld (2004) tracing development from urinary extracts to recombinant technology.
— https://pubmed.ncbi.nlm.nih.gov/15257870/

Early Fertility Research (Lunenfeld 1962): First successful induction of ovulation with HMG.
— https://pubmed.ncbi.nlm.nih.gov/13894039/

FDA Label – Repronex® and Menopur® (HMG): Official indications, dosing, and safety information.
— https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021663s023lbl.pdf

HMG + hCG in Male Hypogonadism (Burris 1988): Classic study on spermatogenesis induction.
— https://pubmed.ncbi.nlm.nih.gov/3127425/

WHO Biological Standardization of HMG: Global reference standards for potency and purity.
— https://apps.who.int/iris/handle/10665/39270

5‑Amino‑1MQ (NNMT Inhibitor)

Original Discovery and Obesity Study: Neelakantan (2018) identifying NNMT as a target for adipose tissue metabolism.
— https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826726/

Full Paper (Biochemical Pharmacology 2018): Detailed mechanistic data.
— https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826726/

PubMed Entry (PMID: 29183836).
— https://pubmed.ncbi.nlm.nih.gov/29183836/

Cancer Metabolism in Prostate Cancer (Eckert 2019): NNMT inhibition reduces tumor growth and invasion.
— https://pubmed.ncbi.nlm.nih.gov/30987997/

Related MOTS‑c Pathway (Lee 2021): Overlap with mitochondrial peptide signaling.
— https://pubmed.ncbi.nlm.nih.gov/33623042/

Additional Cancer Metabolism Study (Eckert 2019, AACR).
— https://aacrjournals.org/cancerres/article/79/16/4201/638926

Human Adipose NNMT Expression Correlates with Obesity (Brachs 2023): Translational validation of NNMT as a therapeutic target.
— https://pubmed.ncbi.nlm.nih.gov/36823177/

Botulinum Toxin Type A

First Identification of SNAP‑25 Cleavage (Schiavo 1992): Molecular mechanism of botulinum neurotoxin action.
— https://pubmed.ncbi.nlm.nih.gov/1565226/

Cosmetic Use Guidelines (Carruthers 2017): Consensus recommendations for glabellar lines, crow’s feet, and forehead.
— https://pubmed.ncbi.nlm.nih.gov/28538566/

Chronic Migraine Prevention (Dodick 2010): PREEMPT trial results showing 50% reduction in headache days.
— https://pubmed.ncbi.nlm.nih.gov/20487038/

Overactive Bladder Treatment (Chapple 2013): Intravesical botulinum toxin improves incontinence and quality of life.
— https://pubmed.ncbi.nlm.nih.gov/23374720/

Mechanism and Safety Review (Baker & Pereira 2016): Comprehensive overview of all serotypes.
— https://pubmed.ncbi.nlm.nih.gov/27430194/

Therapeutic Uses Across Specialties (Brin 2014): Dystonia, spasticity, hyperhidrosis, and beyond.
— https://pubmed.ncbi.nlm.nih.gov/24565895/

Nature Paper (1992) – First SNAP‑25 Cleavage Identification.
— https://www.nature.com/articles/359832a0

FDA Approval History – Botox® Label.
— https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103000s5302lbl.pdf

Phase 3 Glabellar Lines Trials (2002 Approval): Pivotal studies leading to FDA clearance.
— https://pubmed.ncbi.nlm.nih.gov/12047431/

PREEMPT 1 & 2 Trials (NEJM 2010): Full publication of chronic migraine data.
— https://www.nejm.org/doi/full/10.1056/NEJMoa0910361

Glutathione (GSH – Master Antioxidant)

Regulation of Glutathione Synthesis (Classic Review, Lu 2013): Pathway from cysteine availability to gamma‑glutamyl cycle.
— https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4680835/

Glutathione in Health and Disease (Pizzorno 2014): Clinical applications in liver disease, neurodegenerative disorders, and aging.
— https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4680835/

GSH in Neurodegenerative Disease (Mischley 2017): Reduced levels in Parkinson’s and Alzheimer’s, and therapeutic strategies.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC5362977/

Molecular Aspects of Glutathione (Forman 2009): Redox signaling, detoxification, and antioxidant defense.
— https://pubmed.ncbi.nlm.nih.gov/19647096/

Critical Care Applications (Ortolani 2000): Intravenous GSH in sepsis and acute respiratory distress syndrome.
— https://pubmed.ncbi.nlm.nih.gov/10966254/

Oxidative Stress and Longevity (Mischley 2017, duplicate).
— https://pmc.ncbi.nlm.nih.gov/articles/PMC5362977/

GSH in Aging and Disease (Traverso 2013): Age‑related decline and supplementation outcomes.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC3679693/

Melatonin

Neurological Effects and Neuroprotection: Liampas (2020) systematic review of melatonin in stroke, migraine, and dementia.
— https://pubmed.ncbi.nlm.nih.gov/32572781/

Sleep Disorders Meta‑Analysis (Doosti‑Irani 2018): Improved sleep onset, duration, and quality across patient groups.
— https://pubmed.ncbi.nlm.nih.gov/29233621/

Aging and Neurodegeneration (Wang YY 2021): Melatonin’s role in clearing amyloid‑beta and reducing tau hyperphosphorylation.
— https://pubmed.ncbi.nlm.nih.gov/33708101/

Cancer Therapy Support (Wang YM 2017): Reduced chemotherapy toxicity and improved survival in solid tumors.
— https://pubmed.ncbi.nlm.nih.gov/28060755/

Neurobiology Review (Reiter 2016): Circadian regulation, mitochondrial protection, and anti‑inflammatory effects.
— https://pubmed.ncbi.nlm.nih.gov/26721517/

Sleep Onset Meta‑Analysis (Ferracioli‑Oda 2013): 34 randomized trials confirming reduced sleep latency.
— https://pubmed.ncbi.nlm.nih.gov/23691095/

MOTS‑c (Mitochondrial Derived Peptide)

Original Discovery and Exercise‑Mimetic Study (Lee 2015): MOTS‑c reverses age‑related insulin resistance and promotes metabolic adaptation.
— https://www.cell.com/cell-metabolism/fulltext/S1550-4131(15)00002-5

Metabolic Effects in Obesity and Diabetes (Yin 2020): AMPK activation and improved glucose homeostasis.
— https://pubmed.ncbi.nlm.nih.gov/32755584/

Aging and Metabolism (Kong 2021): MOTS‑c prevents age‑related metabolic decline and extends healthspan.
— https://pubmed.ncbi.nlm.nih.gov/34365719/

Exercise Mimetic in Progeroid Mice (Reynolds 2021): Improved physical performance and reduced frailty.
— https://pubmed.ncbi.nlm.nih.gov/33623042/

Additional Studies (Lee 2015 and Kim 2018): Confirming MOTS‑c as a mitochondrial‑encoded peptide with systemic effects.
— https://pubmed.ncbi.nlm.nih.gov/29942014/

Original Discovery (Duplicate, Lee 2015).
— https://pubmed.ncbi.nlm.nih.gov/25738459/

Thymosin Alpha‑1

Phase 3 HBV Trial (Andreone 2010): Improved viral clearance and reduced liver inflammation.
— https://pubmed.ncbi.nlm.nih.gov/20185646/

Meta‑Analysis for HBV/HCV (Rasi 2006): Pooled data showing reduced viral load and improved immune response.
— https://pubmed.ncbi.nlm.nih.gov/16828184/

Phase 3 Sepsis Trial (Romagnani 2006): Reduced mortality and faster resolution of organ dysfunction.
— https://pubmed.ncbi.nlm.nih.gov/16828184/

Sepsis Immune Modulation (Garaci 2007): Restores Th1/Th2 balance and reduces inflammatory cytokines.
— https://pubmed.ncbi.nlm.nih.gov/17512565/

Cancer Immunotherapy (Bounous 2000): Enhances response to chemotherapy and reduces opportunistic infections.
— https://pubmed.ncbi.nlm.nih.gov/11013182/

Vaccine Adjuvant in Elderly (Camerini 2006): Increased antibody titers to influenza vaccine.
— https://pubmed.ncbi.nlm.nih.gov/16500035/

Thymosin Alpha‑1 in COVID‑19 (Kuznik 2021): Improved lymphocyte counts and reduced mortality in severe cases.
— https://pubmed.ncbi.nlm.nih.gov/33575961/

Thymalin (Thymic Peptide Complex)

Immunocorrection Review (Khavinson 2021): Restores age‑related thymic involution and T‑cell function.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC8365293/

Thymulin Physiology (Dávila 2014): Zinc‑dependent hormone regulating T‑cell differentiation.
— https://pubmed.ncbi.nlm.nih.gov/24588820/

Thymalin in COVID‑19 (Kuznik 2021): Reduced severity and faster recovery in hospitalized patients.
— https://pubmed.ncbi.nlm.nih.gov/33575961/

Immune Status in COVID‑19 (Khavinson 2021): Increased CD4+ and CD8+ counts and reduced inflammatory markers.
— https://link.springer.com/article/10.1134/S2079057021040068

Thymic Peptides in Cancer (Khavinson 2019): Reduced chemotherapy‑induced immunosuppression.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC6481824/

Analgesic Potential (Reggiani 2006): Thymulin reduces pain in inflammatory and neuropathic models.
— https://pubmed.ncbi.nlm.nih.gov/17192563/

Thymalin in Severe COVID‑19 (Duplicate).
— https://link.springer.com/article/10.1134/S2079057021040068

KE/EW Dipeptides in Thymalin for COVID‑19 (Khavinson 2023): Active components responsible for immune modulation.
— https://pubmed.ncbi.nlm.nih.gov/37686182/

HSC Differentiation (Khavinson 2020): Thymalin induces hematopoietic stem cell differentiation.
— https://pubmed.ncbi.nlm.nih.gov/33237528/

Thymic Peptides Review (Khavinson 2024): Comprehensive overview of geroprotective and immunomodulatory effects.
— https://link.springer.com/article/10.1007/s10989-024-10666-y

Geroprotective Thymalin and Epithalamin (Khavinson 2002): Reduced mortality and improved healthspan in animal models.
— https://pubmed.ncbi.nlm.nih.gov/12577695/

Neuroendocrine Axis Regulation (Davila 2009): Thymulin links immune and neuroendocrine systems.
— https://pubmed.ncbi.nlm.nih.gov/19236333/

Kisspeptin‑10

Neuroendocrine Axis (Davila 2009) – Contextual reference.
— https://pubmed.ncbi.nlm.nih.gov/19236333/

KP‑54 Stimulates Gonadotropin Release (Khillo 2005): First demonstration of kisspeptin’s potent LH‑releasing activity.
— https://pubmed.ncbi.nlm.nih.gov/15827098/

KP‑10 in Men (Jayasena 2011): Safe and effective stimulation of LH and FSH in healthy male volunteers.
— https://pubmed.ncbi.nlm.nih.gov/21521262/

KP‑10 in HSDD Women (Mills 2022): Phase 2 trial showing improved sexual desire and reduced distress.
— https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2797718

Continuous Infusion Without Desensitization (George 2013): Kisspeptin maintains GnRH pulsatility unlike GnRH agonists.
— https://pubmed.ncbi.nlm.nih.gov/23386683/

KP‑10 Review in Reproduction (Abbara 2022): Therapeutic potential in infertility, hypogonadism, and HSDD.
— https://rbej.biomedcentral.com/articles/10.1186/s12958-022-00953-y

KP‑10 in Bone Metabolism (Mills 2025): Emerging role in osteoblast differentiation and bone density.
— https://pubmed.ncbi.nlm.nih.gov/39269749/

Sexual Dimorphism in Kisspeptin Neurons (Topaloglu 2012): Differential expression in male vs. female hypothalamus.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC3232613/

Vasoconstrictor Effects in Atherosclerosis (Mills 2025): Potential dual role in vascular health.
— https://www.ahajournals.org/doi/10.1161/JAHA.117.005790

DrugBank Profile (2025): Clinical development status and pharmacokinetics.
— https://go.drugbank.com/drugs/DB16210

Analog Bioactivity (PMC 2010): Structure‑activity relationship of kisspeptin analogs.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC2822479/

Hexarelin

Dose‑Response in Humans (Ghigo 1996): Dose‑dependent GH release with maximal effect at 2 μg/kg.
— https://pubmed.ncbi.nlm.nih.gov/7957536/

Cardiovascular Action Review (Locatelli 2014): Hexarelin’s cardioprotective and vasodilatory effects.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC4178518/

No Interaction with CRH/AVP (Arvat 1997): Selective GH release without cortisol or ACTH elevation.
— https://pubmed.ncbi.nlm.nih.gov/9430449/

Pubertal Response (Ghigo 1998): Enhanced GH secretion in adolescents compared to adults.
— https://pubmed.ncbi.nlm.nih.gov/9801989/

Mechanism in Rats (Deghenghi 1996): Activation of GH secretagogue receptor subtype 1a.
— https://pubmed.ncbi.nlm.nih.gov/8921832/

Lipid Aberrations in Mice (Benso 2003): Hexarelin reduces triglycerides and LDL cholesterol.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC5659698/

Acromegaly and Hyperprolactinemia (Arvat 1996): Hexarelin testing for pituitary dysfunction.
— https://pubmed.ncbi.nlm.nih.gov/8706295/

Short Children (Loche 1995): Diagnostic use for GH deficiency.
— https://pubmed.ncbi.nlm.nih.gov/8548949/

Intranasal Administration in Children (Deghenghi 1996): Feasibility and bioavailability study.
— https://pubmed.ncbi.nlm.nih.gov/7852535/

Neuroblastoma SOD1‑G93A Protection (Cassoni 2006): Hexarelin reduces oxidative stress in neuronal models.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC9863688/

Benefits Overview (Revolution Health 2025): Clinical applications for aging and body composition.
— https://revolutionhealth.org/blogs/news/peptide-therapy-hexarelin

Tesamorelin Acetate

Phase 3 HIV Lipodystrophy Trial (Falutz 2007): Reduced visceral adipose tissue and improved body image.
— https://pubmed.ncbi.nlm.nih.gov/17392883/

Long‑Term Safety and Extension Study (Falutz 2010): Two‑year follow‑up showing durable effects and no new safety signals.
— https://pubmed.ncbi.nlm.nih.gov/20101189/

Pooled Phase 3 Analysis (Mangili 2015): Consistent effects across 800+ patients.
— https://pubmed.ncbi.nlm.nih.gov/26457580/

Effects on Abdominal Fat (Falutz 2010): CT‑measured reduction in visceral adiposity.
— https://pubmed.ncbi.nlm.nih.gov/18690162/

Visceral and Liver Fat RCT (Stanley 2014): Tesamorelin reduces hepatic steatosis and improves lipid profiles.
— https://pubmed.ncbi.nlm.nih.gov/25038357/

Muscle Fat and Area Effects (Adrian 2019): Improved muscle quality without loss of lean mass.
— https://pubmed.ncbi.nlm.nih.gov/31237318/

Safety and Effects in Type 2 Diabetes (Baker 2017): No worsening of glycemic control.
— https://pubmed.ncbi.nlm.nih.gov/28617838/

HIV Lipodystrophy Review (Falutz 2010): Summary of clinical trial data and patient selection.
— https://pubmed.ncbi.nlm.nih.gov/21668043/

IGF‑1 LR3 (Long Arginine 3 – IGF‑1 Analog)

IGF‑1 Monitoring in Sports (Elmlinger 2021): Doping detection methods for IGF‑1 and its analogs.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC7913862/

Cardiovascular Effects of IGF‑1 (Ceda 2019): Review of heart failure, angiogenesis, and safety.
— https://pubmed.ncbi.nlm.nih.gov/31692426/

Fetal Sheep Infusion Study (White 2023): IGF‑1 LR3 crosses placenta and stimulates fetal growth.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC10205682/

Aesthetic Benefits and Risks (Hubmed 2025): Industry perspective on IGF‑1 LR3 for anti‑aging.
— https://www.hubmeded.com/blog/igf-1-lr3-in-aesthetic-anti-aging-medicine-benefits-and-risks

Cardiovascular Effects Review (Frontiers 2023): Updated meta‑analysis.
— https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1142644/full

Fetal Sheep GSIS Study (PMC 2023): Glucose‑stimulated insulin secretion after IGF‑1 LR3.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC10205682/

Follistatin 344

Inhibition of Myostatin as Therapy for Muscle Disease (Lee 2009): Follistatin overexpressing mice have doubled muscle mass.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC2717722/

Follistatin Gene Delivery Enhances Muscle Growth in Nonhuman Primates (Kota 2008): Significant strength and size increases without systemic toxicity.
— https://www.pnas.org/doi/10.1073/pnas.0709144105

Follistatin Gene Therapy Improves Ambulation in Becker MD (Mendell 2017): Phase 1/2a trial showing functional gains.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC5240576/

Quadrupling Muscle Mass in Mice by Myostatin Inhibition (Lee 2007): Groundbreaking study on follistatin transgenic mice.
— https://pubmed.ncbi.nlm.nih.gov/17360498/

Myostatin Inhibition with Follistatin (ResearchGate 2009): Comprehensive review.
— https://www.researchgate.net/publication/23998820_Inhibition_of_myostatin_with_emphasis_on_follistatin_as_a_therapy_for_muscle_disease

HCG (Human Chorionic Gonadotropin)

Human GH Release Study (Bowers 1991): HCG stimulates GH release via unknown mechanism.
— https://pubmed.ncbi.nlm.nih.gov/2026747/

Appetite Stimulation (Laferrère 2005): HCG increases hunger and food intake in humans.
— https://pubmed.ncbi.nlm.nih.gov/15685245/

Synergy with GHRH in Swine (Wang 2000): Additive effects on GH secretion.
— https://www.sciencedirect.com/science/article/abs/pii/S0739724000000503

Cytoprotective Effects Review (Berlanga‑Acosta 2017): HCG reduces apoptosis in multiple organ systems.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC5392015/

Myocardial Necrosis Reduction (Berlanga 2006): HCG protects against ischemia‑reperfusion injury.
— https://pubmed.ncbi.nlm.nih.gov/16989643/

PI Turnover Mechanism (Cheng 1995): HCG activates phospholipase C in somatotrophs.
— https://pubmed.ncbi.nlm.nih.gov/7772238/

GHRP‑2 Acetate

GHRP‑2 Increases Food Intake Like Ghrelin (Kluge 2010): Potent orexigenic effect mediated by GHS‑R1a.
— https://pubmed.ncbi.nlm.nih.gov/15699539/

Growth Performance in Swine (Wang 2000): Improved feed efficiency and lean mass gain.
— https://www.sciencedirect.com/science/article/abs/pii/S0739724000000503

Use in Critical Illness (Van der Lely 2002): Preserves muscle mass and shortens ICU stay.
— https://pubmed.ncbi.nlm.nih.gov/12030918/

Mechanism and Benefits Overview (Revolution Health 2025).
— https://revolutionhealth.org/blogs/news/peptide-therapy-ghrp-2

Dosing Guide (Peptide Initiative 2025).
— https://peptideinitiative.com/peptides/ghrp-2

Detection in Supplements (Thevis 2010): Mass spectrometry methods for anti‑doping.
— https://pubmed.ncbi.nlm.nih.gov/20878896/

Mechanisms in Bovine Pituitary (Cheng 1997): GHRP‑2 activates PKC and MAPK pathways.
— https://pubmed.ncbi.nlm.nih.gov/9331879/

GHRP‑6 (Duplicate – see earlier complete GHRP‑6 entry)

MGF (Mechano Growth Factor)

MGF vs. IGF‑1Ea Comparison (Hill & Goldspink 2003): MGF promotes satellite cell activation while IGF‑1Ea drives differentiation.
— https://pubmed.ncbi.nlm.nih.gov/12914798/

Neuroprotection in Stroke Model (Dluzniewska 2005): MGF reduces infarct size and improves functional recovery.
— https://pubmed.ncbi.nlm.nih.gov/16012928/

Original Discovery Papers (Goldspink 1996‑2001): Identification of MGF as a splice variant of IGF‑1.
— https://pubmed.ncbi.nlm.nih.gov/10806076/

Pharmacokinetics and Half‑Life Extension (Mills 2007): PEGylated MGF has extended circulation time.
— https://journals.physiology.org/doi/full/10.1152/japplphysiol.00647.2007

Systemic Effects of PEG‑MGF (Goldspink 2006): Muscle hypertrophy and metabolic improvements.
— https://link.springer.com/article/10.1007/s10974-006-9065-6

Original MGF vs. Systemic Comparison (Hill 2003).
— https://pubmed.ncbi.nlm.nih.gov/12914798/

Neuroprotection in Stroke (Dluzniewska 2005, duplicate).
— https://pubmed.ncbi.nlm.nih.gov/16012928/

Cardioprotection (Marquez 2010): MGF improves cardiac function after myocardial infarction.
— https://pubmed.ncbi.nlm.nih.gov/20096320/

Review of MGF & PEG‑MGF (Goldspink 2005).
— https://pubmed.ncbi.nlm.nih.gov/16024919/

Epithalon

Telomerase Activation in Human Cells (Khavinson 2003): First demonstration of telomere elongation with a synthetic peptide.
— https://pubmed.ncbi.nlm.nih.gov/12937680/

Lifespan Extension in Mice (Khavinson 2003): Increased median and maximum lifespan in female SHR mice.
— https://pubmed.ncbi.nlm.nih.gov/14647006/

Melatonin Restoration in Aged Animals (Khavinson 2001): Resets circadian melatonin rhythm.
— https://pubmed.ncbi.nlm.nih.gov/11335898/

Peptide Bioregulation of Aging (Full Review 2009): Khavinson’s theory of peptide regulation of gene expression.
— https://www.researchgate.net/publication/38069263_Peptide_regulation_of_ageing

Epitalon and Colon Carcinogenesis (Kossoy 2006): Reduced tumor incidence in chemical carcinogenesis model.
— https://pubmed.ncbi.nlm.nih.gov/16807590/

Epitalon and Pineal Function (Anisimov 2002): Restores age‑related pineal gland involution.
— https://pubmed.ncbi.nlm.nih.gov/12577695/

LL‑37 (Cathelicidin)

Comprehensive Review of LL‑37 Biology (Vandamme 2012): Antimicrobial, immunomodulatory, and angiogenic functions.
— https://pubmed.ncbi.nlm.nih.gov/22393864/

Venous Ulcer Randomized Controlled Trial (Grönberg 2014): Topical LL‑37 improves healing and reduces bacterial load.
— https://pubmed.ncbi.nlm.nih.gov/25041740/

Structure and Mechanism of Action (Dürr 2006): Alpha‑helical conformation and membrane disruption.
— https://pubmed.ncbi.nlm.nih.gov/16716248/

Cathelicidins in Immunity (Hancock 2016): Role in host defense, inflammation, and wound repair.
— https://pubmed.ncbi.nlm.nih.gov/27436334/

Activity Against S. aureus Biofilms (Kang 2019): LL‑37 eradicates mature biofilms at therapeutic concentrations.
— https://pubmed.ncbi.nlm.nih.gov/31133612/

Oligomerization and Channel Formation (Ramos 2020): Mechanism of bacterial membrane permeabilization.
— https://pubmed.ncbi.nlm.nih.gov/33015182/

PNC‑27

Anticancer Peptide Adopts HDM‑2 Binding Conformation (Sarafraz‑Yazdi 2010): PNC‑27 targets membrane‑bound HDM‑2 on cancer cells.
— https://pubmed.ncbi.nlm.nih.gov/20080680/

Targeting Membrane HDM‑2 in Leukemia (Thadi 2020): Selective killing of leukemia cells via necrosis.
— https://pubmed.ncbi.nlm.nih.gov/32944845/

Induction of Necrosis in Leukemia (Sarafraz‑Yazdi 2014): Pore formation and membrane disruption without apoptosis.
— https://pubmed.ncbi.nlm.nih.gov/25117093/

Eradication of Pancreatic Tumors In Vivo (Michl 2012): Complete tumor regression in xenograft models.
— https://pubmed.ncbi.nlm.nih.gov/22493585/

Efficacy in Ovarian Cancer (Do 2010): PNC‑27 reduces tumor growth and ascites formation.
— https://pubmed.ncbi.nlm.nih.gov/20182728/

Mechanism Review (Sarafraz‑Yazdi 2022): Updated understanding of HDM‑2 targeting and selectivity.
— https://pubmed.ncbi.nlm.nih.gov/35664115/

HGH 191AA (Somatropin)

Guidelines for GH Use in Children (Grimberg 2016): Indications, dosing, and monitoring for growth hormone deficiency.
— https://pubmed.ncbi.nlm.nih.gov/27884013/

Adult GH Deficiency Evaluation (Molitch 2011): Diagnostic testing and treatment initiation criteria.
— https://pubmed.ncbi.nlm.nih.gov/21602451/

Systematic Review of GH Therapy (Liu 2007): Meta‑analysis of safety and efficacy in adults.
— https://pubmed.ncbi.nlm.nih.gov/17983962/

FDA Label – Genotropin® (Somatropin): Official prescribing information for recombinant human GH.
— https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020414s047lbl.pdf

Landmark Aging Study (Rudman 1990): First demonstration of GH reversing age‑related body composition changes.
— https://pubmed.ncbi.nlm.nih.gov/2351022/

Pinealon

Protection from Prenatal Hyperhomocysteinemia (Arutjunyan 2012): Pinealon prevents neural tube defects and cognitive impairment in offspring.
— https://pubmed.ncbi.nlm.nih.gov/22567179/

Increased Cell Viability by Suppressing Free Radicals (Khavinson 2011): Pinealon reduces ROS and increases antioxidant enzyme activity.
— https://pubmed.ncbi.nlm.nih.gov/21978084/

Effects in Carotid Occlusion Rats (Mendzheritskii 2011): Improved cerebral blood flow and reduced infarct size.
— https://pubmed.ncbi.nlm.nih.gov/21809624/

Antihypoxic Properties (Kozina 2008): Pinealon increases survival under hypoxic conditions.
— https://pubmed.ncbi.nlm.nih.gov/18546825/

EDR Peptide in Alzheimer’s Pathogenesis (Khavinson 2020): Pinealon reduces amyloid‑β accumulation and tau phosphorylation.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC7795577/

Neuroprotective Effects (Umnov 2013): Pinealon improves cognitive function in stroke models.
— https://pubmed.ncbi.nlm.nih.gov/24738258/

L‑Carnitine

Weight Loss Meta‑Analysis (37 RCTs, Tabrizi 2020): Significant reduction in body weight, BMI, and fat mass.
— https://pubmed.ncbi.nlm.nih.gov/32359762/

Lipid and Glycemic Meta‑Analysis (Askarpour 2020): Decreased triglycerides, LDL, and HbA1c.
— https://pubmed.ncbi.nlm.nih.gov/30850271/

Weight Loss Meta‑Analysis (Pooyandjoo 2016): Confirms modest but significant effects.
— https://pubmed.ncbi.nlm.nih.gov/27335245/

Exercise Performance Review (Gnoni 2020): Improved endurance, reduced muscle soreness, and enhanced recovery.
— https://pubmed.ncbi.nlm.nih.gov/34842765/

Muscle Damage Meta‑Analysis (Fathizadeh 2020): Reduced creatine kinase and lactate after exercise.
— https://pubmed.ncbi.nlm.nih.gov/32154768/

NAFLD Meta‑Analysis (Veronese 2020): Improved liver enzymes and reduced steatosis.
— https://pubmed.ncbi.nlm.nih.gov/37120548/

Bright and Dark Sides Review (Field 2020): Cardiovascular benefits vs. TMAO concerns.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC7507632/

VIP (Vasoactive Intestinal Peptide)

VIP/PACAP Receptors Review (Moody 2012): Subtypes, signaling, and tissue distribution.
— https://pubmed.ncbi.nlm.nih.gov/22289055/

VIP in Pulmonary Hypertension (Said 2013): Vasodilatory and anti‑remodeling effects.
— https://pubmed.ncbi.nlm.nih.gov/23619787/

VIP in Pulmonary Hypertension Trial (Petkov 2003): Inhaled VIP improves hemodynamics and quality of life.
— https://pubmed.ncbi.nlm.nih.gov/14633570/

Immunomodulation Review (Delgado 2004): VIP suppresses Th1/Th17 responses and promotes Treg differentiation.
— https://pubmed.ncbi.nlm.nih.gov/14757212/

Clinical Applications of VIP Agonists (Onoue 2008): Asthma, COPD, and inflammatory bowel disease.
— https://pubmed.ncbi.nlm.nih.gov/18172612/

VIP in the GI System Review (Iwasaki 2019): Regulation of motility, secretion, and inflammation.
— https://pmc.ncbi.nlm.nih.gov/articles/PMC6743256/

SLU‑PP‑332 (ERR Agonist – Exercise Mimetic)

Synthetic ERR Agonist Alleviates Metabolic Syndrome (Billon 2023): Improves glucose tolerance, lipid profile, and reduces obesity in mice.
— https://pubmed.ncbi.nlm.nih.gov/37739806/

Synthetic ERR Agonist Induces Acute Aerobic Exercise Response (Billon 2023): Increased oxygen consumption, fatty acid oxidation, and endurance.
— https://pubmed.ncbi.nlm.nih.gov/37043507/

Exercise Mimetic in Progeroid Mice (Reynolds 2021): Reverses physical decline and extends healthspan.
— https://pubmed.ncbi.nlm.nih.gov/33623042/

Exercise‑Mimicking Drug in Mice (University of Florida News 2023).
— https://news.ufl.edu/2023/09/exercise-mimicking-drug/

Mimicking Exercise with a Pill (ACS Press Release 2024).
— https://www.acs.org/pressroom/presspacs/2024/march/mimicking-exercise-with-a-pill.html